The immunosuppressant rapamycin, alone or with transforming growth factor-β, enhances osteoclast differentiation of RAW264.7 Monocyte-macrophage cells in the presence of RANK-ligand

Calcified Tissue International

Volumn 71, Issue 5, 2002, Pages 437-446

  Shui, C ^a   Riggs, B L ^a   Khosla, S ^a  

^a MAYO CLINIC   (United States)

Author keywords

Immunosuppressant; Osteoclast; RANK ligand; Transforming growth factor

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CALCITONIN RECEPTOR; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; LIGAND; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; RAPAMYCIN; RECEPTOR PROTEIN; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTICLE; BONE DEVELOPMENT; BONE METABOLISM; CELL DIFFERENTIATION; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; MACROPHAGE; MONOCYTE; MOUSE; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

ACID PHOSPHATASE; ANIMALS; CARRIER PROTEINS; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG SYNERGISM; IMMUNOSUPPRESSIVE AGENTS; ISOENZYMES; MEMBRANE GLYCOPROTEINS; MICE; MONOCYTES; OSTEOCLASTS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CALCITONIN; RNA, MESSENGER; SIROLIMUS; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0041663764     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-001-1138-3     Document Type: Article

References (65)

1. Epstein S (1996) Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton. J Bone Miner Res 11:1-7
2. Epstein S, Shane E, Bilezikian JP (1995) Organ transplantation and osteoporosis. Curr Opin Rheumatol 7:255-261
3. Rodino MA, Shane E (1998) Osteoporosis after organ transplantation. Am J Med 104:459-469
4. Parker CR, Freemont AJ, Blackwell PJ, Grainge MJ, Hosking DJ (1999) Cross-sectional analysis of renal transplantation osteoporosis. J Bone Miner Res 14:1943-1951
5. Pichette V, Bonnardeaux A, Prudhomme L, Gagne M, Cardinal J, Ouimet D (1996) Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am J Kidney Dis 28:105-114
6. Keogh JB, Tsalamandris C, Sewell RB, Jones RM, Angus PW, Nyulasi IB, Seeman E (1999) Bone loss at the proximal femur and reduced lean mass following liver transplantation: a longitudinal study. Nutrition 15:661-664
7. Shane E, Rivas MC, Silverberg SJ, Kim TS, Staron RB, Bilezikian JP (1993) Osteoporosis after cardiac transplantation. Am J Med 94:257-264
8. Shane E, Rivas M, Staron RB, Silverberg SJ, Seibel MJ, Kuiper J, Mancini D, Addesso V, Michler RE, Factor-Litvak P (1996) Fracture after cardiac transplantation: a prospective longitudinal study. J Clin Endocrinol Metab 81:1740-1746
9. Shane E, Rivas M, McMahon DJ, Staron RB, Silverberg SJ, Seibel MJ, Mancini D, Michler RE, Aaronson K, Addesso V, Lo SH (1997) Bone loss and turnover after cardiac transplantation. J Clin Endocrinol Metab 82:1497-1506
10. Stempfle HU, Werner C, Echtler S, Wehr U, Rambeck WA, Siebert U, Uberfuhr P, Angermann CE, Theisen K, Gartner R (1999) Prevention of osteoporosis after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation 68:523-530
11. Aringer M, Kiener HP, Koeller MD, Artemiou O, Zuckermann A, Wieselthaler G, Klepetko W, Seidl G, Kainberger F, Bernecker P, Smolen JS, Pietschmann P (1998) High turnover bone disease following lung transplantation. Bone 23:485-488
12. Sibley RK, Berry GJ, Tazelaar HD, Kraemer MR, Theodore J, Marshall SE, Billingham ME, Starnes VA (1993) The role of transbronchial biopsies in the management of lung transplant recipients. J Heart Lung Transplant 12:308-324
13. Spira A, Gutierrez C, Chaparro C, Hutcheon MA, Chan CK (2000) Osteoporosis and lung transplantation: a prospective study. Chest 117:476-481
14. Stern JM, Chesnut CH III, Bruemmer B, Sullivan KM, Lenssen PS, Aker SN, Sanders J (1996) Bone density loss during treatment of chronic GVHD. Bone Marrow Transplant 17:395-400
15. Weilbaecher KN (2000) Mechanisms of osteoporosis after hematopoietic cell transplantation. Biol Blood Marrow Transplant 6:165-174
16. Cooper DK, Novitzky D, Rose AG, Reichart BA (1986) Acute pulmonary rejection precedes cardiac rejection following heart-lung transplantation in a primate model. J Heart Transplant 5:29-32
17. Trulock EP (1993) Management of lung transplant rejection. Chest 103:1566-1576
18. Bowman AR, Sass DA, Dissanayake IR, Ma YF, Liang H, Yuan Z, Jee WS, Epstein S (1997) The role of testosterone in cyclosporin-induced osteopenia. J Bone Miner Res 12:607-615
19. Katz IA, Epstein S (1992) Post transplantation bone disease. J Bone Miner Res 7:123-126
20. Katz IA, Li M, Joffe I, Stein B, Jacobs T, Liang XG, Ke HZ, Jee W, Epstein S (1994) Influence of age on cyclosporin A-induced alterations in bone mineral metabolism in the rat in vivo. J Bone Miner Res 9:59-67
21. Romero DF, Buchinsky FJ, Rucinski B, Cvetkovic M, Bryer HP, Liang XG, Ma YF, Jee WS, Epstein S (1995) Rapamycin: a bone sparing immunosuppressant? J Bone Miner Res 10:760-768
22. hiebaud D, Krieg MA, Gillard-Berguer D, Jacquet AF, Goy JJ, Burckhardt P (1996) Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. Eur J Clin Invest 26:549-555
23. Ogawa T, Tokuda M, Tomizawa K, Matsui H, Itano T, Konishi R, Nagahata S, Hatase O (1998) Osteoblastic differentiation is enhanced by rapamycin in rat osteoblastlike osteosarcoma (ROS17/2.8) cells. Biochem Biophys Res Commun 249:226-230
24. Nacher M, Aubia J, Serrano S, Marinoso ML, Hernandez J, Bosch J, Diez A, Puig JM, Lloveras J (1994) Effect of cyclosporine A on normal human osteoblasts in vitro. Bone Miner 26:231-243
25. McCauley LK, Rosol TJ, Capen CC (1992) Effects of cyclosporin A on rat osteoblasts (ROS 17/2.8 cells) in vitro. Calcif Tissue Int 51:291-297
26. Epstein S, Schlosberg M, Fallon M, Thomas S, Movsowitz C, Ismail F (1990) 1,25 Dihydroxyvitamin D3 modifies cyclosporine-induced bone loss. Calcif Tissue Int 47:152-157
27. Joffe I, Katz I, Sehgal S, Bex F, Kharode Y, Tamasi J, Epstein S (1993) Lack of change ofcancellous of cancellous bone volume with short-term use of the new immunosuppressant rapamycin in rats. Calcif Tissue Int 53:45-52
28. Withold W, Degenhardt S, Heins M, Grabensee B, Reinauer H (1995) Monitoring of bone resorption after renal transplantation by measuring the urinary excretion of pyridinium cross-links. Eur J Clin Chem Clin Biochem 33:15-21
29. Withold W, Wolf HH, Kollbach S, Heyll A, Schneider W, Reinauer H (1996) Monitoring of bone metabolism after bone marrow transplantation by measuring two different markers of bone turnover. Eur J Clin Chem Clin Biochem 34:193-197
30. Bertolini DR, Badger A, High W (1993) Effect of immunomodulators on bone in the rapidly growing rat. J Bone Miner Res 8 (suppl 1):S315
31. Hofbauer LC, Shui C, Riggs BL, Dunstan CR, Spelsberg TC, O'Brien T, Khosla S (2001) Effects of immunosuppressants on receptor activator of NF-κB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 280:334-339
32. Quinn JM, Itoh K, Udagawa N, Hausler K, Yasuda H, Shima N, Mizuno A, Higashio K, Takahashi N, Suda T, Martin TJ, Gillespie MT (2001) Transforming growth factor βaffects osteoclast differentiation via direct and indirect actions. J Bone Miner Res 16:1787-1794
33. Sells Galvin RJ, Gatlin CL, Horn JW, Fuson TR (1999) TGF-β enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF. Biochem Biophys Res Commun 265:233-239
34. 1. J Cell Biochem 83:320-325
35. Chen YG, Liu F, Massague J (1997) Mechanism of TGF β receptor inhibition by FKBP12. EMBO J 16:3866-3876
36. Wang T, Donahoe PK, Zervos AS (1994) Specific interaction of type I receptors of the TGF-β family with the immunophilin FKBP-12. Science 265:674-676
37. Yao D, Dore JJ Jr, Leof EB (2000) FKBP12 is a negative regulator of transforming growth factor-β receptor internalization. J Biol Chem 275:13149-13154
38. Shevde NK, Bendixen AC, Dienger KM, Pike JW (2000) Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci 97:7829-7834
39. Srivastava S, Toraldo G, Weitzmann MN, Cenci S, Ross FP, Pacifici R (2001) Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-κB ligand (RANKL)-induced JNK activation. J Biol Chem 276:8836-8840
40. Huber DM, Bendixen AC, Pathrose P, Srivastava S, Dienger KM, Shevde NK, Pike JW (2001) Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology 142:3800-3808
41. Wright DC, Deol HS, Tuch BE (1999) A comparison of the sensitivity of pig and human peripheral blood mononuclear cells to the antiproliferative effects of traditional and newer immunosuppressive agents. Transpl Immunol 7:141-147
42. Redinbaugh MG, Turley RB (1986) Adaptation of the bicinchoninic acid protein assay for use with microtiter plates and sucrose gradient fractions. Analyt Biochem 153:267-271
43. Lindunger A, MacKay CA, Ek-Rylander B, Andersson G, Marks SC Jr (1990) Histochemistry and biochemistry of tartrate-resistant acid phosphatase (TRAP) and tartrateresistant acid adenosine triphosphatase (TrATPase) in bone, bone marrow and spleen: implications for osteoclast ontogeny. Bone Miner 10:109-119
44. Lee SK, Goldring SR, Lorenzo JA (1995) Expression of the calcitonin receptor in bone marrow cell cultures and in bone: a specific marker of the differentiated osteoclast that is regulated by calcitonin. Endocrinology 136:4572-4581
45. Yamin M, Gorn AH, Flannery MR, Jenkins NA, Gilbert DJ, Copeland NG, Tapp DR, Krane SM, Goldring SR (1994) Cloning and characterization of a mouse brain calcitonin receptor complementary deoxyribonucleic acid and mapping of the calcitonin receptor gene. Endocrinology 135:2635-2643
46. Hicok KC, Thomas T, Gori F, Rickard DJ, Spelsberg TC, Riggs BL (1998) Development and characterization of conditionally immortalized osteoblast precursor cell lines from human bone marrow stroma. J Bone Miner Res 13:205-217
47. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176
48. Quinn JM, Elliott J, Gillespie MT, Martin TJ (1998) A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 139:4424-4427
49. Cooper MH, Gregory SH, Starzl TE, Wing EJ (1994) Rapamycin but not FK506 inhibits the proliferation of mononuclear phagocytes induced by colony-stimulating factors. Transplantation 57:433-439
50. Crowe A, Bruelisauer A, Duerr L, Guntz P, Lemaire M (1999) Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos 27:627-632
51. Hausen B, Boeke K, Berry GJ, Segarra I, Benet LZ, Christians U, Morris RE (1999) Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. Transplantation 67:956-962
52. Hausen B, Ikonen T, Briffa N, Berry GJ, Christians U, Robbins RC, Hook L, Serkova N, Benet LZ, Schuler W, Morris RE (2000) Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability. Transplantation 69:76-86
53. Klaushofer K, Hoffmann O, Stewart PJ, Czerwenka E, Koller K, Peterlik M, Stern PH (1987) Cyclosporine A inhibits bone resorption in cultured neonatal mouse calvaria. J Pharmacol Exp Ther 243:584-590
54. Orcel P, Bielakoff J, Modrowski D, Miravet L, de Vernejoul MC (1989) Cyclosporin A induces in vivo inhibition of resorption and stimulation of formation in rat bone. J Bone Miner Res 4:387-391
55. Orcel P, Denne MA, de Vernejoul MC (1991) Cyclosporin-A in vitro decreases bone resorption, osteoclast formation, and the fusion of cells of the monocyte-macrophage lineage. Endocrinology 128:1638-1646
56. Stewart PJ, Green OC, Stern PH (1986) Cyclosporine A inhibits calcemic hormone-induced bone resorption in vitro. J Bone Miner Res 1:285-291
57. Awumey EM, Moonga BS, Sodam BR, Koval AP, Adebanjo OA, Kumegawa M, Zaidi M, Epstein S (1999) Molecular and functional evidence for calcineurin-A α and β isoforms in the osteoclast: novel insights into cyclosporin A action on bone resorption. Biochem Biophys Res Commun 254:248-252
58. Dumont FJ, Su Q (1996) Mechanism of action of the immunosuppressant rapamycin. Life Sci 58:373-395
59. Menaa C, Kurihara N, Roodman GD (2000) CFU-GM-derived cells form osteoclasts at a very high efficiency. Biochem Biophys Res Commun 267:943-946
60. Quesniaux VF, Wehrli S, Steiner C, Joergensen J, Schuurman HJ, Herrman P, Schreier MH, Schuler W (1994) The immunosuppressant rapamycin blocks in vitro responses to hematopoietic cytokines and inhibits recovering but not steady-state hematopoiesis in vivo. Blood 84:1543-1552
61. Centrella M, Horowitz MC, Wozney JM, McCarthy TL (1994) Transforming growth factor-β gene family members and bone. Endocr Rev 15:27-39
62. Stockwell BR, Schreiber SL (1998) TGF-β-signaling with small molecule FKBP12 antagonists that bind myristoylated FKBP12-TGF-β type I receptor fusion proteins. Chem Biol 5:385-395
63. Fiorelli G, Ballock RT, Wakefield LM, Sporn MB, Gori F, Masi L, Frediani U, Tanini A, Bernabei PA, Brandi ML (1994) Role for autocrine TGF-β in regulating differentiation of a human leukemic cell line toward osteoclast-like cells. J Cell Physiol 160:482-490
64. Fruman DA, Burakoff SJ, Bierer BE (1994) Immunophilins in protein folding and immunosuppression. FASEB J 8:391-400
65. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC Jr, Abraham RT (1996) Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J 15:5256-5267